death. Its diagnosis and treatment often produce psychological stresses resulting from the actual symptoms of the disease, as well as the patient's and family's perceptions of the disease and its stigma. Patient fears include worries about death, dependency, disfigurement, disability, disruption of relationships, and, finally, discomfort or pain in later stages of illness. 1 Each of these has particular meaning for aging individuals who may experience these fears in the context of retirement, widowhood, other medical disabilities, and other losses.
The patient's ability to manage these stresses depends on medical, psychological, and social issues. Factors to be considered include: 1) the disease itself (i.e., site, symptoms, clinical course type of treatment required); 2) previous level of adjustment, especially to medical illness; 3) the threat that cancer poses in attaining life-phase tasks and goals such as retirement and grandparenthood; 4) cultural and religious attitudes; 5) the presence of emotionally supportive persons in the patient's environment; 6) the patient's potential for physical and psychological rehabilitation; 7) the patient's own personality and coping style; 8) previous experience with cancer; and 9) other losses. 2 Today, patients and families appear more interested in treatment issues and quality of life, both during and after treatment. In this article, we discuss late life depression, anxiety, and delirium and treatments related to elderly patients coping with cancer.
Depression
In the geriatric population, depressive symptoms may coexist with, mask, amplify, or be the hallmark of physical disabilities and illness. 3 Symptoms often tend to improve as physical status improves. Somatic complaints more commonly may be part of the defining symptoms of a depression in an elderly patient than in a younger one. Physiologic changes associated with depression such as fatigue, poor appetite, and decreased motivation may Optimism about improved survival from cancer has increased. Currently, cancer treatment includes multimodal treatment regimens (surgery, chemotherapy, radiation), drugs used in high doses or administered by various routes (intrathecal, intracarotid, or intrahepatic), and innovative procedures such as bone marrow transplantation, immunotherapy, and vaccine therapy, all adding to a large number of cancer survivors. However, even with tremendous improvement in screening techniques and treatment, a cancer diagnosis may shatter the dream of a dignified old age for elderly patients who grew up in an era in which the word "cancer" was unmentionable. For these people, cancer means hopelessness, pain, fear, and increase risk factors for developing new medical diseases and can worsen the course and treatment outcome of an already established medical illness. It is important to remember that a major depression is not a normal part of aging. Depressed mood and sadness can be appropriate responses in a cancer patient, but when a patient's normal depressed mood is severe and is accompanied by hopeless, despondent, or guilty feelings and suicidal thoughts, this is a major depression and should be treated. Oncologists and oncology nurses often underestimate the morbidity caused by depression. 4 Risk factors of depression in the elderly include loss of spouse, functional disability, inadequacy of emotional support, uncontrolled pain, poor physical condition, advanced illness, previous history of depression, other life stresses or losses, family history of depression or suicide, and taking medications known to cause depression. Increasing disability and health deterioration are strong predictors of depression. 5 Also at risk are patients with pancreatic, head and neck, and lung cancers. Higher levels of symptom severity, lower levels of prior physical functioning, and greater physical functioning deficits have predicted higher levels of depressive symptomatology. 6 Depression appears to plateau between the ages of 65 and 75, when it tends to increase. 5, 7 The reported rates of major depression in patients with cancer vary widely. Although not all cancer patients are depressed, most are distressed at the crisis points of illness, such as at times of diagnosis, recurrence, treatment failure, and transition from curative to palliative care. During these crisis points, patients may experience a brief period of denial or despair followed by distress with a mixture of depressed mood and anxiety, insomnia, anorexia, and irritability. These patients report difficulty performing daily activities, with lingering thoughts about the uncertainty of the future, which is then followed by a return to usual patterns of adaptation. These symptoms last for days to several weeks, after which usual patterns of adaptation return. This normal response is highly variable.
The NCCN has recommended the use of the Distress Thermometer and Problem List as a screening tool for distress in cancer patients. 8 This tool has been piloted in prostate cancer patients 9 and is currently undergoing testing for validation and reliability in a collaborative study of cancer centers. Other tools that may help busy clinicians screen for depression in the elderly include the Geriatric Depression Scale (GDS), the Hospital Anxiety and Depression Scale (HADS), and the Center for Epidemiologic Studies-Depression Scale (CESD). About 25% of cancer patients continue to have high levels of anxiety and depression in syndromes called adjustment disorders. These syndromes do not meet criteria for major disorders but may interfere significantly with the patient's functioning, persisting for weeks to months.
One study examining the prevalence of depression in hospitalized cancer patients, using criteria that eliminated physical symptoms, 10 found that 24% of these patients were severely depressed, 18% were moderately depressed, and 14% had depressive symptoms of "sadness." The remaining 44% showed no symptoms of depression despite their cancer. The factor most significantly related to severe depression was physical function, although distinguishing vegetative signs of depression from physical symptoms is difficult at greater levels of illness, making interpretation of findings difficult. In general, approximately 25% of all cancer patients, irrespective of their hospital and physical status, may be experiencing significant depression. 11, 12 Symptoms of depression can be caused by several medical conditions such as uncontrolled pain, which is the most common cause of depressed mood in cancer patients. It is accompanied by anxiety and a sense of anguish that life is intolerable unless their pain is relieved. Patients also interpret a new or increasingly severe pain as a sign that the cancer has progressed, causing greater depression and hopelessness. Suicide is a genuine risk in these patients, especially if they do not believe that efforts are being made to control the pain or that relief is possible. With advancing age, prevalence of attempted suicide appears to decrease, but the rate of completed suicide increases. Suicidal ideation and major depressive symptoms usually abate when the pain is controlled. In addition to uncontrolled pain, other factors that tend to place a cancer patient at high risk for suicide are poor prognosis, advanced illness, depression and hopelessness, delirium, prior psychiatric history, history of major depression, divorce, previous suicide attempts or family history of suicide, recent bereavement, alcohol abuse, a sense of loneliness and isolation, and few social supports.
Other causes of depression include hypercalcemia from bone metastasis, other electrolyte imbalances, deficient vitamin B12 or folate, hypothyroidism or adrenal insufficiency, and paraneoplastic syndromes. Elderly patients may be taking various medications that can affect mood. Glucocorticoids such as prednisone and dexamethasone cause alterations in mood, including severe depression. Interferon and interleukin-2, in addition to producing cognitive deficits, may cause depressive symptoms. Barbiturates, benzodiazepines, and antibiotics can cause depressive symptoms. Chemotherapeutic agents that can induce depression include vincristine, vinblastine, procarbazine, and L-asparaginase; whole brain radiation may cause depression as well.
The biologic correlates of depression or neurovegetative symptoms (such as decreased appetite, poor sleep, fatigue, loss of energy, loss of libido, and psychomotor slowing) may be unreliable in cancer patients. In advanced illness, when both depression and debilitation are present, it is difficult to decide which is primary. Thus, the psychological symptoms of depression take on greater diagnostic value and can include dysphoric mood, hopelessness, worthlessness, guilt, and suicidal ideation. [13] [14] [15] However, the strategy of relying on the psychological or cognitive signs and symptoms of depression for diagnostic specificity is itself not without problems. How is the clinician to interpret feelings of hopelessness in the older dying patient when there is no hope for cure or recovery? Although many patients lose hope of a cure, they are able to maintain hope for better symptom control. For many patients, hope and a sense of worth is contingent on the ability to find continued meaning in their day-to-day existence. A "demoralization syndrome" is said to occur when patients experience a sense of existential despair, hopelessness, and loss of meaning and purpose in life. 16 Hopelessness that is pervasive and accompanied by a sense of despair or despondency is more likely to represent a symptom of a depressive disorder. Similarly, patients often state that they feel they are burdening their families unfairly, causing them great pain and inconvenience. Those beliefs are more likely to represent a symptom of depression if the patient feels that their life never had any worth or that they are being punished for evil things they have done.
Depression and cognitive impairment may occur concurrently in the elderly. It is important to distinguish between cognitive changes caused by dementia and other general medical conditions and cognitive problems that will remit when the depression improves.
Treatment of Depression in Cancer Patients
Depression in older cancer patients is optimally managed using a combination of supportive psychotherapy, cognitive and behavioral techniques, and antidepressant medications. Psychotherapeutic treatment is directed at helping the patient adapt to the stresses they are undergoing and to help strengthen their coping abilities (Table 1) . Supportive techniques such as active listening with supportive comments can be readily applied by oncologists and oncology nurses. Cognitive behavioral therapy challenges faulty thought processes and attempts to reframe them in a healthier manner. Group therapy for cancer patients, caregivers, and families may be advantageous, allowing individuals to receive support from others facing similar problems. Apart from improving emotional well-being, patients undergoing group psychotherapy have been noted by some to have greater longevity; these findings have yet to be replicated. It is not uncommon for the patient and family to benefit from pastoral counseling. For more intensive psychotherapy, a referral to a psychologist, psychiatrist, or social worker is recommended.
In general, antidepressant drugs are as effective in older people with depression as in younger patients with depression. The general rule of thumb for dosing antidepressants in elderly cancer patients is "start low and go slow." It is important to educate patients about the therapeutic response time of these medications. It can take at least 2 weeks for most antidepressants to work and possibly up to 5 or 6 weeks for a good trial at any dose. If patients are not aware of this they may become prematurely nonadherent with the drug. Table  2 outlines the common antidepressants and psychostimulants used in these patients. Selective Serotonin Reuptake Inhibitors: In the past few years, the newer antidepressants, the selective serotonin reuptake inhibitors (SSRIs), fluoxetine, sertraline, paroxetine, and citalopram, are used by more clinicians as a first choice in older, medically ill patients because of their efficacy and fewer serious side effects than tricyclic antidepressants (TCAs). The SSRIs do not carry the same risks of cardiac arrhythmias, hypotension, and troublesome anticholinergic effects such as urinary retention, memory impairment, sedation and reduced awareness, as do the TCAs. The most common side effects of the SSRIs, usually dose related, include mild gastric distress and nausea, increased intestinal motility, and brief periods of increased headache and insomnia (and sometimes hypersomnia). Some patients may experience anxiety, tremor, restlessness, and akathisia (which although rare, can be problematic for the patient with comorbid Parkinson's disease). SSRIs can cause sexual dysfunction in men and women, a side effect that often leads to cessation of the medication. This side effect may be a problem for older sexually active patients.
Although some patients can have some transient appetite suppression and subsequent weight loss, the anorectic properties of these drugs have not been a limiting factor in this population. The SSRIs have a wider margin of safety than the TCAs in the event of an overdose and, therefore, they do not require therapeutic drug level monitoring. The shorter halflife of some SSRIs such as sertraline and citalopram, allows for faster clearance should this be necessary in the medically ill. Paroxetine has no active metabolites and therefore is removed also from a patient's system relatively quickly on discontinuation. Because most of these drugs are strongly protein bound, consideration must be given to their interactions with other medications such as coumadin, digoxin, and cisplatin. All of the SSRIs can inhibit the hepatic isoenzyme P450 11D6. This is important with respect to dose/plasma level ratios and drug interactions, because the SSRIs are dependent on hepatic metabolism. It is important to consider drug-drug interactions, especially in the elderly, who may be on multiple medication regimens and have more than one physician. SSRIs should be avoided with the chemotherapeutic agent procarbazine, which has MAOI-like properties. Serotonin-Norepinephrine Reuptake Inhibitors and Other Newer Generation Antidepressants: Venlafaxine is a potent inhibitor of neuronal serotonin and norepinephrine reuptake. It is similar to TCAs in terms of efficacy, without the same uncomfortable side effects. Compared with the SSRIs, its protein binding is very low; therefore, few protein bindinginduced drug interactions are expected. Like other antidepressants, venlafaxine should not be used in patients receiving MAOIs. Its side effect profile tends to be generally well tolerated. At higher doses it has the potential to produce hypertension, and patients should be screened routinely.
Mirtazapine is a sedating antidepressant and is useful in depressed patients with associated anxiety and insomnia. It has few gastrointestinal and sexual side effects and may induce weight gain. It is usually dosed at bedtime because of its sedating properties. Neutropenia has been reported; however, no studies to date indicate that mirtazapine is contraindicated in cancer patients.
Bupropion has an activating profile that makes it useful in lethargic medically ill patients, but it should be avoided in patients with a history of seizure disorders and brain tumors and in patients who are malnourished. It may cause anxiety or restlessness in some patients. Bupropion is less cardiotoxic than the TCAs. Tricyclic Antidepressants: Until recently, TCAs have been the cornerstone for treating depression in the general cancer setting. These medications are associated with a side effect profile that can be particularly troublesome for elderly patients at therapeutic doses. Currently, TCAs are most often used in the cancer population to treat neuropathic pain syndrome.
The anticholinergic actions of TCAs can cause confusion as well as serious tachycardia, and the quinidine-like effects of TCAs can lead to arrhythmias. Postural hypotension and dizziness may occur also; these are of particular concern for the frail, volumedepleted patient who is at risk for falls and possible osteoporosis-related fractures. For patients already exposed to a variety of sedating agents (such as, narcotic analgesics, antiemetics, anxiolytics, and neuroleptics) TCAs can accentuate the overall cumulative sedating effects of these medications.
Tricyclic antidepressants should also be started at low doses and increased slowly every five to seven days, until a therapeutic dose is attained or side effects become a dose-limiting factor. Although dosages may be monitored using blood levels, undergoing more blood tests may be an added burden for a cancer patient. Psychostimulants: The psychostimulants (dextroamphetamine, methylphenidate, pemoline, and modafinil) offer an alternative and effective pharmacologic approach to the treatment of depression in cancer patients. [17] [18] [19] These drugs have a more rapid onset of action than traditional antidepressants and are often energizing. They are most helpful in the treatment of depression in cancer patients with advanced disease and those in whom dysphoric mood is associated with severe psychomotor slowing and even mild cognitive impairment. Psychostimulants have been shown to improve attention, concentration, and overall performance on neuropsychological testing in the medically ill. 20 In relatively low doses, psychostimulants stimulate appetite, promote a sense of well-being, and improve feelings of weakness and fatigue in cancer patients. Psychostimulants are usually dosed in the morning and at noon if needed, to avoid sleep problems. The dosage is slowly increased over several days until a desired effect is achieved or until side effects such as overstimulation, anxiety, tremor, insomnia, mild increase in blood pressure and pulse rate, or confusion intervene. Tolerance will develop, and dose adjustment may be necessary. An additional benefit of such stimulants as methylphenidate and dextroamphetamine are that they have been shown to reduce seda-tion secondary to opioid analgesics and provide adjuvant analgesia in cancer patients. 21 Contraindications to methylphenidate include a history of a seizure disorder and cardiac problems such as atrial fibrillation. The newest psychostimulant is modafinil, an atypical stimulant whose primary indication is for narcolepsy. It is chemically unrelated to the amphetamines; however, its mechanism of action is still unclear. It does not carry a risk of seizures, but as with other stimulants, a major contraindication is atrial fibrillation.
Pemoline is a less-potent stimulant with little abuse potential. It was commonly used until recently. However, it has been found to cause liver toxicity and therefore should be used with caution. Monamine Oxidase Inhibitors: Monamine oxidase inhibitors (MAOIs) have been considered a less desirable alternative for treating depression in cancer patients. Patients who receive MAOIs must avoid foods rich in tyramine, sympathomimetic drugs (amphetamines, methylphenidate) and medications containing phenylpropanolamine and pseudoephedrine. The combination of these agents with MAOIs may cause hypertensive crisis, leading to strokes and fatalities. MAOIs in combination with opioid analgesics also have been associated with myoclonus and delirium. These drugs must therefore be used together cautiously. 22 The use of meperidine is absolutely contraindicated in patients taking MAOIs and can lead to hyperpyrexia, cardiovascular collapse, and death.
Choosing an Antidepressant
Antidepressant selection in the elderly cancer population should be based on a number of variables (Table 3) . Choosing an antidepressant may be based on whether a patient or a family member has responded well to an antidepressant in the past. Other factors that should be considered include: the patient's overall health and cognitive abilities; social and financial resources, which are often limited in this patient population; and any other existing psychiatric conditions (such as substance abuse, psychosis, or anxiety disorders). The elderly might require longer treatment trials than other patient populations, so patience is important for both the patient and practitioner.
It is useful to note if there is a need for physical symptom control (neuropathic pain, fatigue, insomnia) in addition to the psychiatric symptoms. These symptoms may be treated at least in part by the antidepressant. In addition, it is helpful to consider the side effect profiles of different antidepressants, including those side effects that may be useful as well as those that should be avoided. For example, if a patient presents with fatigue or sedation, the most appropriate agent may be an energizing SSRI (such as fluoxetine or paroxetine), bupropion, or a psychostimulant. Consider mirtazapine or a calming SSRI like citalopram in a patient who is experiencing anxiety. If the patient presents with gastric problems, an appropriate agent may be mirtazapine or a TCA. Mirtazapine, which also comes in a soluble tablet preparation that does not need to be swallowed, or a TCA can be used in patients complaining of loss of appetite.
Amitriptyline and other TCAs can be used in patients with neuropathic pain. 23 Mirtazapine and trazodone are effective in the treatment of insomnia. 24 Anxiety disorders and panic attacks respond to SSRIs. Paroxetine has been shown to prevent and counteract depression in patients receiving interferon alfa. 25 SSRIs and psychostimulants have been effective in the treatment of cachexia and anorexia. Some of the SSRIs (sertraline, fluoxetine, paroxetine) and venlafaxine have been found to help with hot flashes either from natural or chemotherapy-induced menopause in women and with hormonally induced flashes in men with prostate cancer. [26] [27] [28] [29] Bupropion slow release formulation may be helpful in patients who want to cut back or discontinue tobacco smoking.
Patients who are unable to swallow pills may be able to take an antidepressant in an elixir (fluoxetine, paroxetine, sertraline, nortriptyline, and amitriptyline). Patients with stomatitis secondary to chemotherapy or radiotherapy or patients with slow intestinal motility or urinary retention should receive an antidepressant with the fewest anticholinergic side effects.
If a patient has received an adequate trial of an antidepressant, that is, a sufficient dose for a sufficient time, but remains depressed, another antidepressant in a different class should be tried. If multiple trials of antidepressants do not work, it may be necessary to consider electroconvulsive therapy (ECT) for patients with depression that is refractory to antidepressants, patients who are extremely suicidal or psychotic, or depressed cancer patients who have significant contraindications to treatment with antidepressant drugs. ECT may achieve a more favorable response than pharmacotherapy for many patients in spite of their medical problems, and is surprisingly safe in older aged patients.
Anxiety
Anxiety is a normal reaction to stressful traumatic events such as receiving a cancer diagnosis. Anxiety may be part of a normal stress response, an acute stress disorder, or an anxiety disorder caused by a general medical condition. It may be a component of delirium or major depression. Normal anxiety also appears at the crisis points in illness mentioned earlier. It may be accompanied by loss of appetite, insomnia, intrusive thoughts about the diagnosis and the future, and decreased ability to concentrate and perform usual activities. Anxiety that persists and causes impairment is considered pathologic. Those individuals who are extremely fearful may be unable to absorb information or cooperate with medical procedures.
Diagnosing anxiety disorders in general in the elderly may be problematic. Older adults are more likely to have comorbid medical and psychological conditions and ongoing pharmacologic treatments that may complicate the symptomatic picture. Although most anxiety disorders in patients with cancer develop after the onset of the cancer, a smaller proportion represents preexisting anxiety disorders.
The differential diagnosis of anxiety in the elderly cancer patient can be complex. Patients in severe pain may appear anxious or agitated; they usually respond to adequate pain control with analgesics. Respiratory distress caused by a pulmonary embolus may present as anxiety and restlessness; although ultimately relieved by medical interventions, these patients often respond symptomatically to an anxiolytic. Sepsis, endocrine abnormalities, hypoglycemia, hypercalcemia, hormone-secreting tumors, and pancreatic cancer also cause anxiety symptoms. Depression, anxiety, and even panic attacks occur in cancer of the pancreas. 30 Many patients on steroids experience anxiety. Withdrawal from narcotics, benzodiazepines, and alcohol results in anxiety and agitation. Neuroleptics such as prochlorperazine and metoclopramide, often used as antiemetics, can cause akathisia or motor restlessness accompanied by subjective feelings of distress and hyperactivity. Anxiety disorders such as phobias and panic disorder that precede the onset of cancer can compromise medical treatment and must be addressed. Patients with claustrophobia may have extreme anxiety in the confined spaces of diagnostic scanning or radiotherapy treatment rooms. Patients may have needle phobias and have avoided medical evaluations for some time because of their fears. Others may have agoraphobia and be unable to tolerate hospitalization. Recall of prior painful or frightening experiences such as military combat or assault are common aspects of post-traumatic stress disorder (PTSD) in cancer patients, especially those undergoing bone marrow transplantation.
Patients with anxiety may benefit from specific behavioral interventions including progressive relaxation, distraction, guided imagery, meditation, biofeedback, and hypnosis. These techniques also are used to treat the anxiety symptoms associated with painful procedures, pain syndromes, medical office visits, waiting for results, and anticipatory fears of chemotherapy and radiation therapy. Other psychotherapeutic techniques such as supportive, insight-oriented, and cognitive behavioral therapy may be helpful to reduce anxiety symptoms and allow for better coping with the cancer. When the need for a diagnostic procedure or treatment is urgent, benzodiazepines should be used cautiously in the elderly (Table 4) .
The most common side effects of benzodiazepines, especially with the longer acting drugs, are sedation and confusion. These occur more frequently in the older patient and in patients with impaired brain or liver function. Longer acting drugs such as diazepam are more likely to cause both confusion and imbalance leading to falls, because the drug tends to accumulate over time. Lorazepam and oxazepam are metabolized by conjugation and excreted by the kidney and thus are better tolerated by patients with impaired hepatic function. Dose-dependent side effects such as drowsiness, confusion, and motor incoordination must be monitored carefully in the elderly cancer patient. Clinicians must keep in mind the synergistic effects of the benzodiazepines with medications that have central nervous system (CNS)-depressant properties such as narcotics and some antidepressants. Elderly patients with dementia, delirium, or brain injury who receive benzodiazepines may experience paradoxical behavioral disturbances such as aggressiveness, irritability, and agitation.
Buspirone, a nonbenzodiazepine anxiolytic, is useful for elderly patients. However, as with antidepressants, there is a lag time between starting the medication and efficacy.
Low-dose neuroleptics are effective in patients with severe anxiety not well controlled by benzodiazepines and in patients unable to tolerate the side effects of benzodiazepines such as sedation or respiratory depression. Risperidone, olanzapine, and quetiapine may be better tolerated than haloperidol.
For the short-term pharmacologic treatment of insomnia in the elderly, the nonbenzodiazepine hypnotic agents zolpidem and zaleplon are often used in preference to benzodiazepines. Antihistamines such as diphenhydramine are not recommended for the treatment of insomnia in the elderly. Although they may help with the initiation of sleep, they work poorly to maintain sleep and are associated with anticholinergic side effects such as urinary retention, confusion, and constipation. Alternatively, trazodone, a heterocyclic antidepressant, may be used as a sedating sleep medication.
Delirium
The essential features of delirium are the acute onset of disordered attention and cognition. Delirium has been characterized as an etiologically nonspecific, global, cerebral dysfunction with disturbances of level of consciousness, attention, thinking, perception, memory, psychomotor behavior, emotion, and the sleep-wake cycle. The disturbance develops over a short period of time (usually hours to days) and tends to fluctuate during the course of the day.
Early symptoms of delirium can be misdiagnosed as anxiety, anger, depression, or psychosis. In any patient showing acute onset of agitation, impaired cognitive function, altered attention span, or a fluctuating level of consciousness, a diagnosis of delirium should be considered. Delirium is common in patients with advanced cancer, and one study found delirium in 25% of hospitalized cancer patients seen in psychiatric consultation and in 85% of terminal cancer patients. 31 Early identification of delirium is imperative, because elderly patients who develop delirium during a hospitalization have been estimated to have a 22% to 76% chance of dying during that hospitalization. 32 The major risk factors for delirium appear to be preexisting cognitive impairment, advanced age, and severity of comorbid medical illness.
Delirium often involves multiple medical etiologies in cancer patients. It can be due either to the direct effects of cancer on the CNS or to indirect CNS effects of the disease or treatments (medications, electrolyte imbalance, failure of a vital organ or system, infection, vascular complications, and preexisting cognitive impairment or dementia). Given the large numbers of drugs that older cancer patients require, even routinely ordered hypnotics may be enough to induce delirium. Narcotic analgesics are common causes of confusional states in the elderly. Chemotherapeutic agents known to cause delirium include methotrexate, fluorouracil, vincristine, vinblastine, bleomycin, BCNU, cisplatinum, asparaginase, procarbazine, and the glucocorticosteroids. [33] [34] [35] [36] [37] Psychiatric side effects of steroids can occur at any time, on any dose, and even during the tapering phase. Prior psychiatric illness or prior disturbance on steroids is not a good predictor of susceptibility to, or the nature of, mental disturbance with steroids. These disorders are often rapidly reversible on dose reduction or discontinuation.
Immunotherapeutic agents such as interleukin-2 can cause delirious symptoms, including hallucinations, disorientation, and confusion. 38 Amphotericin B, used regularly for the treatment of fungal infections in immunologically compromised cancer patients, can cause delirium, particularly with intrathecal administration. It may be difficult to distinguish the CNS effects of antifungal medication from those of fever, CNS infection, or metabolic abnormalities. Acyclovir can cause neurotoxicity, marked by lethargy, agitation, tremor, and disorientation. Paraneoplastic syndromes (limbic and bulbar encephalitides, subacute cerebellar degeneration) are remote effects of primary tumors (most commonly small-cell lung cancer or breast cancer, but possibly including stomach, uterine, renal, testicular, thyroid, or colon cancer). They may be caused by the cancer inducing an antibody that cross reacts with antigens in normal tissue. Symptoms may include a mental status change, hallucinations, cognitive deficits, depression, and anxiety. 39 Differentiating between delirium and dementia may be difficult because they frequently share such common clinical features as impaired memory, thinking, judgment, and orientation. Dementia appears in relatively alert individuals with little or no clouding of consciousness. The temporal onset of symptoms in dementia is more subacute or chronically progressive, and the sleep-wake cycle seems less impaired. Most prominent in dementia are difficulties in short-and long-term memory, impaired judgment, and abstract thinking, as well as disturbed higher cortical functions (such as aphasia and apraxia). Occasionally one will encounter delirium superimposed on an underlying dementia. Therefore, it is essential to have information from family members, caretakers, or medical records to determine if symptoms of dementia were preexisting.
Delirium, in contrast to dementia, is conceptualized as a reversible process. Reversibility of the process of delirium is often possible even in the patient with advanced illness; however, it may not be reversible in the last 24 to 48 hours of life.
The Mini Mental State Examination (MMSE) is useful for screening for cognitive failure, but it does not distinguish between delirium and dementia. 40 The MMSE provides a quantitative assessment of the cognitive performance and capacity of a patient and is a measure of severity of cognitive impairment. It is also most sensitive to cortical dementias such as Alzheimer's disease and less sensitive in detecting subcortical deficits such as those found in AIDS dementia. The MMSE assesses five general cognitive areas, including orientation, registration, attention and calculation, recall, and language. The Confusion Assessment Method (CAM), the Delirium Rating Scale (DRS), and the Memorial Delirium Assessment Scale (MDAS) are other tools that may help the clinician identify delirium.
Managing Delirium
A standard approach for managing delirium in the cancer patient includes a search for underlying causes, correction of those causes, and management of delirium symptoms. Fluid and electrolyte balance, nutrition, and vitamins may be helpful. Measures to help reduce anxiety and disorientation (structure and familiarity) may include a quiet, well-lit room with familiar objects, a visible clock or calendar, and the presence of family. However, these supportive techniques are usually not effective alone, and symptomatic treatment with neuroleptic or sedative medications are necessary (Table 5 ). Sedation may be necessary to relieve severe agitation or insomnia. 41 Judicious use of physical restraints, along with continuous nursing observation may be necessary and useful.
The side effects of neuroleptics are often class specific. The side effects of high-potency neuroleptics such as haloperidol include the extrapyramidal effects of akathisia and cogwheeling, tardive dyskinesia, torsades de pointe, and neuroleptic malignant syndrome. Acute dystonia is rare in the elderly. Low-potency neuroleptics such as chlorpromazine also have a wide range of side effects, including anticholinergic effects, orthostatic hypotension, akathisia, cardiac effects, sedation, tardive dyskinesia, and neuroleptic malignant syndrome. The side effects of the newer, atypical antipsychotics are markedly reduced; these drugs are, therefore, better tolerated. Risperidone may cause some extrapyramidal side effects, though fewer than the highpotency neuroleptics. Sedation, glucose intolerance, and weight gain have been associated with olanzapine. Sedation is seen in patients taking quetiapine. Haloperidol, a potent dopamine blocker, is still the drug of choice in the treatment of delirium in the medically ill. [41] [42] [43] [44] Haloperidol in low doses, 1 to 3 mg, is usually effective in targeting agitation, paranoia, and fear. Typically 0.5 mg to 1.0 mg haloperidol (orally, intravenously, intramuscularly, or subcutaneously) is administered, with repeat doses every 45 to 60 minutes titrated against target symptoms. An intravenous route can facilitate rapid onset of medication effects, though it is not Federal Drug Administration (FDA) approved. Electrocardiograms should be monitored periodically because the QTc interval may be prolonged. If intravenous access is unavailable, one can start with intramuscular administration and switch to the oral route when possible. The majority of delirious patients can be managed with oral haloperidol. Parenteral doses are approximately twice as potent as oral doses.
A common strategy in the management of agitation related to delirium is to add parenteral lorazepam to a regimen of haloperidol. Lorazepam along with haloperidol may be more effective in rapidly sedating an agitated delirious patient. In a double blind, randomized comparison trial of haloperidol versus chlorpromazine versus lorazepam, Breitbart et al 45 showed that lorazepam alone was ineffective in treating delirium, and in fact contributed to worsening delirium and cognitive impairment. However, in low doses, both neuroleptic drugs were highly effective in controlling the symptoms of delirium and improving cognitive function.
Newer atypical agents such as risperidone, olanzapine, quetiapine, and ziprasidone show promise because of improved side effect profiles, in particular fewer extrapyramidal symptoms. However, their use in delirious patients is limited by lack of parenteral administration. Olanzapine is available in a wafer that is easily dissolved in the mouth, making administration in agitated patients more reliable. Risperidone is available in liquid form. Ziprasidone is a new atypical antipsychotic available in an intramuscular formulation approved for acutely agitated patients with schizophrenia, but it may be useful in the agitated cancer patient. Most of the atypical antipsychotic medications can prolong the QTc interval moderately.
Olanzapine has been shown to be an effective treatment for delirium. 46 However, in an open label trial, 47 patients over 70 years old, those with hypoactive delirium, and those with CNS spread of cancer as the delirium etiology had a significantly poorer response to olanzapine. Olanzapine use was limited by sedation; however, no patients had extrapyramidal symptoms.
As with antidepressants, neuroleptics may be chosen for the side effect profile, for example, using a sedating agent like olanzapine, quetiapine, or chlorpromazine for agitated patients. Less-sedating agents such as haloperidol or risperidone may be useful for a patient with hypoactive delirium. Practitioners trying to minimize the risk of cardiovascular side effects may consider olanzapine or quetiapine. For patients with hepatic dysfunction, chlorpromazine or other low-potency neuroleptics should be avoided. If the means of medication administration are limited (i.e., the patient cannot or refuses to take medication by mouth), intravenous haloperidol or the wafer version of olanzapine may be considered.
Conclusions
As cancer treatments have become more aggressive and successful, the psychological and psychiatric sequelae of cancer diagnosis, relapse and survivorship have been increasingly recognized. This article highlights some of the psychiatric issues elderly patients with cancer may face during the illness. We hope that earlier recognition of these issues by oncology physicians and nurses will lead to less distress and overall improvement in the quality of life of people with cancer.
Psychotherapeutic and psychopharmacologic interventions are optimal in treating anxiety and depression in elderly cancer patients, although there may be more resistance to these treatments for older patients. In particular, antidepressants and neuroleptic medications have an important role in treating depression and delirium. Oncologists should be aware of the indications for psychotropic medications, the possible side effects or drug interactions of psychiatric medications, and how to obtain psychiatric consultation if needed. Finally, more psycho-oncologic intervention research is needed in elderly cancer patients to better assess the efficacy and safety of these therapies.
